ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: WAS-related disorders
Gene/Gene Panel: WAS
Context: Pediatric
Date
Status
Release
Outcomes-Interventions
Notes
2022/02/09
Released
1.1.3
P
WAS-related morbidity and mortality (males only) (GroupA)
Referral to hematology for clinical scoring of WAS-related conditions to determine treatment (GroupA) 9CC
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
WAS ⇔ 0010294 NEUTROPENIA, SEVERE CONGENITAL, X-LINKED; SCNX
Moderate Actionability
Moderate Actionability
WAS ⇔ 0010518 WISKOTT-ALDRICH SYNDROME; WAS
Moderate Actionability
Moderate Actionability
WAS ⇔ 0010743 THROMBOCYTOPENIA 1; THC1
Moderate Actionability
Moderate Actionability
2022/02/09
Released (Under revision)
1.1.2
P
WAS-related morbidity and mortality (males only) (GroupA)
Referral to hematology for clinical scoring of WAS-related conditions to determine treatment (GroupA) 9CC
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
WAS ⇔ 0010294 NEUTROPENIA, SEVERE CONGENITAL, X-LINKED; SCNX
Moderate Actionability
Moderate Actionability
WAS ⇔ 0010518 WISKOTT-ALDRICH SYNDROME; WAS
Moderate Actionability
Moderate Actionability
WAS ⇔ 10743 THROMBOCYTOPENIA 1; THC1
Moderate Actionability
Moderate Actionability
2021/12/01
Released
1.1.2
P
WAS-related morbidity and mortality (males only) (GroupA)
Referral to hematology for clinical scoring of WAS-related conditions to determine treatment (GroupA) 9CC
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
WAS ⇔ 0010294 NEUTROPENIA, SEVERE CONGENITAL, X-LINKED; SCNX
Moderate Actionability
Moderate Actionability
WAS ⇔ 0010518 WISKOTT-ALDRICH SYNDROME; WAS
Moderate Actionability
Moderate Actionability
WAS ⇔ 10743 THROMBOCYTOPENIA 1; THC1
Moderate Actionability
Moderate Actionability
2021/09/15
Released (Under revision)
1.1.1
P
WAS-related morbidity and mortality (males only) (GroupA)
Referral to hematology for clinical scoring of WAS-related conditions to determine treatment (GroupA) 9CC
2020/04/16
Released
1.1.1
P
WAS-related morbidity and mortality (males only) (GroupA)
Referral to hematology for clinical scoring of WAS-related conditions to determine treatment (GroupA) 9CC
2019/10/03
Released (Under revision)
1.1.0
P
WAS-related morbidity and mortality (males only)
Referral to hematology for clinical scoring of WAS-related conditions to determine treatment 9CC
Internal system migration related to merging adult and pediatric contexts.
2019/04/04
Released
1.1.0
P
WAS-related morbidity and mortality (males only)
Referral to hematology for clinical scoring of WAS-related conditions to determine treatment 9CC
Internal system migration related to merging adult and pediatric contexts.
2019/03/07
Released
1.0.0
P
WAS-related morbidity and mortality (males only)
Referral to hematology for clinical scoring of WAS-related conditions to determine treatment 9CC
2019/02/20
In Preparation
N/A
¤ Powered by BCM's Genboree.